<li>abiraterone<p>abiraterone increases levels of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.</p></li><li>abobotulinumtoxina<p>aripiprazole increases effects of abobotulinumtoxina by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.<span><br><br></span>abobotulinumtoxina decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>abobotulinumtoxina decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>acarbose<p>aripiprazole, acarbose. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>aclidinium<p>aclidinium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>albiglutide<p>aripiprazole, albiglutide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>albuterol<p>aripiprazole increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>alfentanil<p>alfentanil and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>alprazolam<p>alprazolam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>amisulpride<p>amisulpride and aripiprazole both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>amisulpride and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>amitriptyline<p>aripiprazole and amitriptyline both increase  sedation. Use Caution/Monitor.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>amobarbital and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>amoxapine<p>aripiprazole and amoxapine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.<span><br><br></span>aripiprazole and amoxapine both increase  sedation. Use Caution/Monitor.</p></li><li>anticholinergic/sedative combos<p>anticholinergic/sedative combos decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>anticholinergic/sedative combos decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>apomorphine<p>aripiprazole and apomorphine both increase  sedation. Use Caution/Monitor.</p></li><li>aprepitant<p>aprepitant will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>arformoterol<p>aripiprazole increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>armodafinil<p>armodafinil will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>artemether/lumefantrine will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>atazanavir<p>atazanavir will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>atracurium<p>atracurium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>atracurium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>atropine<p>atropine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>atropine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>atropine iv/im<p>aripiprazole increases effects of atropine iv/im by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.<span><br><br></span>atropine iv/im decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>atropine iv/im decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>azelastine<p>azelastine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>baclofen<p>baclofen and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>bambuterol<p>aripiprazole increases and bambuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>belladonna alkaloids<p>belladonna alkaloids decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>belladonna alkaloids decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>belladonna and opium<p>belladonna and opium and aripiprazole both increase  sedation. Use Caution/Monitor.<span><br><br></span>belladonna and opium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>belladonna and opium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>benazepril<p>aripiprazole, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>benperidol<p>aripiprazole and benperidol both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and benperidol both increase  sedation. Use Caution/Monitor.</p></li><li>benzphetamine<p>aripiprazole increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>bosentan<p>bosentan will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>brompheniramine<p>brompheniramine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>buclizine<p>buclizine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>buclizine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of buclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>budesonide<p>budesonide will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>buprenorphine<p>buprenorphine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>buprenorphine buccal<p>buprenorphine buccal and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>bupropion<p>bupropion will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>butabarbital and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>butalbital<p>butalbital will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>butalbital and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>butorphanol<p>butorphanol and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>caffeine<p>aripiprazole increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>captopril<p>aripiprazole, captopril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure.</p></li><li>carbinoxamine<p>carbinoxamine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>carisoprodol<p>carisoprodol and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>chloral hydrate<p>chloral hydrate and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>chlordiazepoxide<p>chlordiazepoxide and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>chlorpheniramine<p>chlorpheniramine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>chlorpromazine<p>aripiprazole and chlorpromazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and chlorpromazine both increase  sedation. Use Caution/Monitor.</p></li><li>chlorpropamide<p>aripiprazole, chlorpropamide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>chlorzoxazone<p>chlorzoxazone and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>cinnarizine<p>cinnarizine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>cisatracurium<p>cisatracurium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>cisatracurium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>clemastine<p>clemastine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>clobazam<p>clobazam will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. <span><br><br></span>aripiprazole, clobazam. Other (see comment). Use Caution/Monitor. 
Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).</p></li><li>clobetasone<p>clobetasone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>clomethiazole<p>aripiprazole and clomethiazole both increase  sedation. Use Caution/Monitor.</p></li><li>clomipramine<p>aripiprazole and clomipramine both increase  sedation. Use Caution/Monitor.</p></li><li>clonazepam<p>clonazepam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>clonidine<p>clonidine, aripiprazole. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.</p></li><li>clorazepate<p>clorazepate and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>clozapine<p>aripiprazole and clozapine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and clozapine both increase  sedation. Use Caution/Monitor.</p></li><li>codeine<p>codeine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>conivaptan<p>conivaptan will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>cortisone<p>cortisone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>crizotinib<p>crizotinib increases levels of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.</p></li><li>crofelemer<p>crofelemer increases levels of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyclizine<p>cyclizine and aripiprazole both increase  sedation. Use Caution/Monitor.<span><br><br></span>cyclizine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>cyclizine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>cyclobenzaprine<p>cyclobenzaprine and aripiprazole both increase  sedation. Use Caution/Monitor.<span><br><br></span>cyclobenzaprine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>cyclosporine<p>cyclosporine will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>cyproheptadine<p>cyproheptadine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>dantrolene<p>dantrolene and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>darifenacin<p>darifenacin will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>darifenacin decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>darifenacin decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>darunavir<p>darunavir will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dasatinib<p>dasatinib will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>deferasirox<p>deferasirox will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>delavirdine<p>delavirdine will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>desipramine<p>aripiprazole and desipramine both increase  sedation. Use Caution/Monitor.</p></li><li>desvenlafaxine<p>desvenlafaxine will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses &lt;100 mg</p></li><li>dexamethasone<p>dexamethasone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dexchlorpheniramine<p>dexchlorpheniramine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>dexfenfluramine<p>aripiprazole increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dexmedetomidine<p>dexmedetomidine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>dexmethylphenidate<p>aripiprazole increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dextroamphetamine<p>aripiprazole increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dextromoramide<p>dextromoramide and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>dhea, herbal<p>dhea, herbal will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>diamorphine<p>diamorphine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>diazepam<p>diazepam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>dichlorphenamide<p>dichlorphenamide and aripiprazole both decrease  serum potassium. Use Caution/Monitor.</p></li><li>dicyclomine<p>dicyclomine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>dicyclomine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>diethylpropion<p>aripiprazole increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>difenoxin hcl<p>difenoxin hcl and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dimenhydrinate<p>dimenhydrinate and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>diphenhydramine<p>diphenhydramine and aripiprazole both increase  sedation. Use Caution/Monitor.<span><br><br></span>diphenhydramine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>diphenhydramine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>diphenoxylate hcl<p>diphenoxylate hcl and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>dipipanone<p>dipipanone and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>dobutamine<p>aripiprazole increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dopamine<p>aripiprazole increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dopexamine<p>aripiprazole increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dosulepin<p>aripiprazole and dosulepin both increase  sedation. Use Caution/Monitor.</p></li><li>doxepin<p>aripiprazole and doxepin both increase  sedation. Use Caution/Monitor.</p></li><li>doxylamine<p>doxylamine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>droperidol<p>aripiprazole and droperidol both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and droperidol both increase  sedation. Use Caution/Monitor.</p></li><li>efavirenz<p>efavirenz will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eliglustat<p>eliglustat increases levels of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of aripiprazole by affecting hepatic enzyme CYP2E1 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.<span><br><br></span>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>enflurane<p>enflurane and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>ephedrine<p>aripiprazole increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ephedrine (pulmonary)<p>aripiprazole increases and ephedrine (pulmonary) decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>epinephrine<p>aripiprazole increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>epinephrine racemic<p>aripiprazole increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>estazolam<p>estazolam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>ethanol<p>aripiprazole and ethanol both increase  sedation. Use Caution/Monitor.</p></li><li>ethotoin<p>ethotoin will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>etomidate<p>etomidate and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>etravirine<p>etravirine will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eucalyptus<p>eucalyptus will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>exenatide injectable solution<p>aripiprazole, exenatide injectable solution. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>exenatide injectable suspension<p>aripiprazole, exenatide injectable suspension. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>fenfluramine<p>aripiprazole increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>fesoterodine<p>fesoterodine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>fesoterodine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>flavoxate<p>flavoxate decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>flavoxate decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fludrocortisone<p>fludrocortisone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fluphenazine<p>aripiprazole and fluphenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and fluphenazine both increase  sedation. Use Caution/Monitor.</p></li><li>flurazepam<p>flurazepam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>formoterol<p>aripiprazole increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>fosamprenavir<p>fosamprenavir will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>glimepiride<p>aripiprazole, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>glipizide<p>aripiprazole, glipizide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>glyburide<p>aripiprazole, glyburide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>glycopyrrolate<p>aripiprazole increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>glycopyrrolate inhaled<p>glycopyrrolate inhaled decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>glycopyrrolate inhaled decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>grapefruit<p>grapefruit will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>griseofulvin<p>griseofulvin will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>guanabenz<p>guanabenz, aripiprazole. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.</p></li><li>guanfacine<p>guanfacine, aripiprazole. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.</p></li><li>haloperidol<p>aripiprazole and haloperidol both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and haloperidol both increase  sedation. Use Caution/Monitor.</p></li><li>henbane<p>henbane decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>henbane decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of henbane by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>hexobarbital and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>homatropine<p>homatropine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>homatropine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of homatropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>hydrocodone<p>hydrocodone and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>hydrocortisone<p>hydrocortisone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>hydromorphone<p>hydromorphone and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>hydroxyzine<p>hydroxyzine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>hyoscyamine<p>hyoscyamine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>hyoscyamine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of hyoscyamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>hyoscyamine spray<p>aripiprazole increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.<span><br><br></span>hyoscyamine spray decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>hyoscyamine spray decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>iloperidone<p>aripiprazole and iloperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and iloperidone both increase  sedation. Use Caution/Monitor.<span><br><br></span>iloperidone increases levels of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>imipramine<p>aripiprazole and imipramine both increase  sedation. Use Caution/Monitor.</p></li><li>incobotulinumtoxina<p>aripiprazole increases effects of incobotulinumtoxina by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.<span><br><br></span>incobotulinumtoxina decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>incobotulinumtoxina decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>indinavir<p>indinavir will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>insulin aspart<p>aripiprazole, insulin aspart. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>insulin degludec<p>aripiprazole decreases effects of insulin degludec by Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin degludec/insulin aspart<p>aripiprazole decreases effects of insulin degludec/insulin aspart by Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin detemir<p>aripiprazole, insulin detemir. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>insulin glargine<p>aripiprazole, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>insulin glulisine<p>aripiprazole, insulin glulisine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>insulin inhaled<p>aripiprazole decreases effects of insulin inhaled by Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin lispro<p>aripiprazole, insulin lispro. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>insulin nph<p>aripiprazole, insulin nph. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>insulin regular human<p>aripiprazole, insulin regular human. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>ipratropium<p>ipratropium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>ipratropium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>isoproterenol<p>aripiprazole increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ketotifen, ophthalmic<p>aripiprazole and ketotifen, ophthalmic both increase  sedation. Use Caution/Monitor.</p></li><li>lapatinib<p>lapatinib will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>levalbuterol<p>aripiprazole increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>levorphanol<p>levorphanol and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>liraglutide<p>aripiprazole, liraglutide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>lisdexamfetamine<p>aripiprazole increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>lofepramine<p>aripiprazole and lofepramine both increase  sedation. Use Caution/Monitor.</p></li><li>lofexidine<p>aripiprazole and lofexidine both increase  sedation. Use Caution/Monitor.</p></li><li>loprazolam<p>loprazolam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>lorazepam<p>lorazepam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>lorcaserin<p>lorcaserin will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lormetazepam<p>lormetazepam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>loxapine<p>aripiprazole and loxapine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and loxapine both increase  sedation. Use Caution/Monitor.</p></li><li>loxapine inhaled<p>aripiprazole and loxapine inhaled both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and loxapine inhaled both increase  sedation. Use Caution/Monitor.</p></li><li>lumefantrine<p>lumefantrine will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>lumefantrine will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>lurasidone<p>lurasidone, aripiprazole.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.</p></li><li>maprotiline<p>aripiprazole and maprotiline both increase  sedation. Use Caution/Monitor.</p></li><li>marijuana<p>marijuana will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>aripiprazole and marijuana both increase  sedation. Use Caution/Monitor.</p></li><li>meclizine<p>meclizine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>meclizine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>melatonin<p>aripiprazole and melatonin both increase  sedation. Use Caution/Monitor.</p></li><li>mepenzolate<p>mepenzolate decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>mepenzolate decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of mepenzolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>meperidine<p>meperidine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>mephobarbital and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>meprobamate<p>aripiprazole and meprobamate both increase  sedation. Use Caution/Monitor.</p></li><li>metaproterenol<p>aripiprazole increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>metaxalone<p>metaxalone and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>metformin<p>aripiprazole, metformin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>methadone<p>methadone and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>methamphetamine<p>aripiprazole increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>methocarbamol<p>methocarbamol and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>methscopolamine<p>methscopolamine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>methscopolamine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of methscopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>methylenedioxymethamphetamine<p>aripiprazole increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>methylphenidate<p>aripiprazole increases and methylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>methylprednisolone<p>methylprednisolone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>metoclopramide<p>aripiprazole and metoclopramide both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mianserin<p>aripiprazole and mianserin both increase  sedation. Use Caution/Monitor.</p></li><li>mibefradil<p>mibefradil will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>midazolam<p>midazolam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>midodrine<p>aripiprazole increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>miglitol<p>aripiprazole, miglitol. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>mirabegron<p>mirabegron will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mirtazapine<p>aripiprazole and mirtazapine both increase  sedation. Use Caution/Monitor.</p></li><li>mitotane<p>mitotane decreases levels of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>modafinil<p>modafinil will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>morphine<p>morphine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>motherwort<p>aripiprazole and motherwort both increase  sedation. Use Caution/Monitor.</p></li><li>moxonidine<p>aripiprazole and moxonidine both increase  sedation. Use Caution/Monitor.</p></li><li>nabilone<p>aripiprazole and nabilone both increase  sedation. Use Caution/Monitor.</p></li><li>nalbuphine<p>nalbuphine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>nateglinide<p>aripiprazole, nateglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>nelfinavir<p>nelfinavir will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nifedipine<p>nifedipine will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nizatidine<p>nizatidine will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>norepinephrine<p>aripiprazole increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>nortriptyline<p>aripiprazole and nortriptyline both increase  sedation. Use Caution/Monitor.</p></li><li>olanzapine<p>aripiprazole and olanzapine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and olanzapine both increase  sedation. Use Caution/Monitor.</p></li><li>onabotulinumtoxina<p>onabotulinumtoxina decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>onabotulinumtoxina decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of onabotulinumtoxina by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>opium tincture<p>opium tincture and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>orphenadrine<p>orphenadrine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>oxazepam<p>oxazepam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>oxcarbazepine<p>oxcarbazepine will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>oxiconazole<p>oxiconazole will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>oxybutynin<p>oxybutynin decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>oxybutynin decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>oxybutynin topical<p>oxybutynin topical decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>oxybutynin topical decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>oxybutynin transdermal<p>oxybutynin transdermal decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>oxybutynin transdermal decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>oxycodone<p>oxycodone and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>oxymorphone<p>oxymorphone and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>paliperidone<p>aripiprazole and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and paliperidone both increase  sedation. Use Caution/Monitor.</p></li><li>pancuronium<p>pancuronium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>pancuronium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of pancuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>papaveretum<p>papaveretum and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>papaverine<p>aripiprazole and papaverine both increase  sedation. Use Caution/Monitor.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b, aripiprazole. Other (see comment). Use Caution/Monitor. 
Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.</p></li><li>pentazocine<p>pentazocine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>pentobarbital and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>perphenazine<p>aripiprazole and perphenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and perphenazine both increase  sedation. Use Caution/Monitor.</p></li><li>phendimetrazine<p>aripiprazole increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>phenobarbital and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>phentermine<p>aripiprazole increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>phenylephrine<p>aripiprazole increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>phenylephrine po<p>aripiprazole increases and phenylephrine po decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>pholcodine<p>aripiprazole and pholcodine both increase  sedation. Use Caution/Monitor.</p></li><li>pimozide<p>aripiprazole and pimozide both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and pimozide both increase  sedation. Use Caution/Monitor.</p></li><li>pioglitazone<p>aripiprazole, pioglitazone. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>pirbuterol<p>aripiprazole increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>posaconazole<p>posaconazole will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>pralidoxime<p>pralidoxime decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>pralidoxime decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of pralidoxime by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>pramlintide<p>aripiprazole, pramlintide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>prednisolone<p>prednisolone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>prednisone<p>prednisone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>primidone<p>primidone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>primidone and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>prochlorperazine<p>aripiprazole and prochlorperazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and prochlorperazine both increase  sedation. Use Caution/Monitor.</p></li><li>promethazine<p>aripiprazole and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>promethazine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>propantheline<p>propantheline decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>propantheline decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>propylhexedrine<p>aripiprazole increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>protriptyline<p>aripiprazole and protriptyline both increase  sedation. Use Caution/Monitor.</p></li><li>pseudoephedrine<p>aripiprazole increases and pseudoephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>quazepam<p>quazepam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>quetiapine<p>aripiprazole and quetiapine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and quetiapine both increase  sedation. Use Caution/Monitor.</p></li><li>quinidine<p>quinidine will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>quinupristin/dalfopristin<p>quinupristin/dalfopristin will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ramelteon<p>aripiprazole and ramelteon both increase  sedation. Use Caution/Monitor.</p></li><li>ranitidine<p>ranitidine will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>rapacuronium<p>rapacuronium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>rapacuronium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of rapacuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>repaglinide<p>aripiprazole, repaglinide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rimabotulinumtoxinb<p>aripiprazole increases effects of rimabotulinumtoxinb by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.<span><br><br></span>rimabotulinumtoxinb decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>rimabotulinumtoxinb decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>risperidone<p>aripiprazole and risperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and risperidone both increase  sedation. Use Caution/Monitor.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rocuronium<p>rocuronium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>rocuronium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of rocuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>rosiglitazone<p>aripiprazole, rosiglitazone. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>rufinamide<p>rufinamide will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>salmeterol<p>aripiprazole increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>saquinavir<p>saquinavir increases levels of aripiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Consider aripiprazole dose reduction by 50%.</p></li><li>saxagliptin<p>aripiprazole, saxagliptin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>scopolamine<p>scopolamine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>scopolamine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of scopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>scullcap<p>aripiprazole and scullcap both increase  sedation. Use Caution/Monitor.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>secobarbital and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>sertindole<p>aripiprazole and sertindole both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and sertindole both increase  sedation. Use Caution/Monitor.</p></li><li>sertraline<p>sertraline will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>shepherd's purse<p>aripiprazole and shepherd's purse both increase  sedation. Use Caution/Monitor.</p></li><li>sitagliptin<p>aripiprazole, sitagliptin. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>solifenacin<p>solifenacin decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>solifenacin decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>sufentanil<p>sufentanil and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>sulpiride<p>aripiprazole and sulpiride both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and sulpiride both increase  sedation. Use Caution/Monitor.</p></li><li>tapentadol<p>tapentadol and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>telithromycin<p>telithromycin will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>temazepam<p>temazepam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>terbutaline<p>aripiprazole increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>terfenadine<p>terfenadine and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>tetrabenazine<p>aripiprazole and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.</p></li><li>thioridazine<p>aripiprazole and thioridazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and thioridazine both increase  sedation. Use Caution/Monitor.</p></li><li>thiothixene<p>aripiprazole and thiothixene both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and thiothixene both increase  sedation. Use Caution/Monitor.</p></li><li>tiotropium<p>tiotropium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>tiotropium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>tolazamide<p>aripiprazole, tolazamide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>tolbutamide<p>aripiprazole, tolbutamide. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>tolterodine<p>tolterodine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>tolterodine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of tolterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>topiramate<p>topiramate will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>aripiprazole and topiramate both increase  sedation. Modify Therapy/Monitor Closely.</p></li><li>tramadol<p>tramadol and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>trazodone<p>aripiprazole and trazodone both increase  sedation. Use Caution/Monitor.</p></li><li>triamcinolone<p>triamcinolone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>triazolam<p>triazolam and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>triclofos<p>triclofos and aripiprazole both increase  sedation. Use Caution/Monitor.</p></li><li>trifluoperazine<p>aripiprazole and trifluoperazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and trifluoperazine both increase  sedation. Use Caution/Monitor.</p></li><li>trimipramine<p>aripiprazole and trimipramine both increase  sedation. Use Caution/Monitor.</p></li><li>troglitazone<p>troglitazone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>troleandomycin<p>troleandomycin will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>trospium chloride<p>trospium chloride decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>trospium chloride decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of trospium chloride by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>tubocurarine<p>tubocurarine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>tubocurarine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of tubocurarine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>vecuronium<p>vecuronium decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>vecuronium decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>aripiprazole increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.</p></li><li>venlafaxine<p>venlafaxine will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>verapamil<p>verapamil will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>voriconazole<p>voriconazole will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>xylometazoline<p>aripiprazole increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>yohimbine<p>aripiprazole increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ziconotide<p>aripiprazole and ziconotide both increase  sedation. Use Caution/Monitor.</p></li><li>ziprasidone<p>aripiprazole and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and ziprasidone both increase  sedation. Use Caution/Monitor.</p></li><li>zotepine<p>aripiprazole and zotepine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.<span><br><br></span>aripiprazole and zotepine both increase  sedation. Use Caution/Monitor.</p></li>